| Guo, Ye |
MRG003-010, NCT05751512: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN |
|
|
| Not yet recruiting | 3 | 180 | RoW | MRG003, Cetuximab injection, Methotrexate Injection | Shanghai Miracogen Inc. | Squamous Cell Carcinoma of the Head and Neck | 08/25 | 12/25 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT04868162: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck |
|
|
| Recruiting | 2 | 120 | RoW | MRG003 | Shanghai Miracogen Inc. | Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | 01/23 | 09/23 | | |
NCT05044897: A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | SI-B001 | Sichuan Baili Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinoma | 06/25 | 06/25 | | |
NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | SI-B001, Paclitaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinoma | 06/25 | 06/25 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
|
|
| Active, not recruiting | 2 | 131 | RoW | HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 05/24 | 06/25 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT06194656: Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 81 | RoW | HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo, Cetuximab injection | Shanghai Institute Of Biological Products | Head and Neck Squamous Cell Carcinoma | 07/26 | 07/26 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
HG146, NCT06781567: Clinical Trial of Administered to Participants with Adenoid Cystic Carcinoma |
|
|
| Recruiting | 2 | 140 | RoW | HG146, HG146 Capsule | HitGen Inc. | Adenoid Cystic Carcinoma, Head and Neck Cancer | 12/28 | 06/29 | | |
NCT06007729: ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 170 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Head and Neck Squamous Cell Carcinoma | 12/25 | 12/27 | | |
NCT04856631: A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer |
|
|
| Recruiting | 1/2 | 88 | RoW | Toripalimab Injection, Cetuximab Solution for infusion | Shanghai Junshi Bioscience Co., Ltd. | Head and Neck Squamous Cell Cancer | 11/22 | 11/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
NCT05867771: A Study of PM1022 in Patients With Advanced Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1022 | Biotheus Inc. | Advanced Tumors | 04/24 | 04/25 | | |
NCT05668858: Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 40 | RoW | SI-B001, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Squamous Cell Carcinoma of Head and Neck | 06/25 | 12/25 | | |
NCT05839106: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1032 injection, PM1032 | Biotheus Inc. | Advanced Tumor | 04/25 | 12/25 | | |
NCT05862831: Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 285 | RoW | PM1003 Injection | Biotheus Inc. | Advanced Solid Tumors | 09/25 | 11/25 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT03869632: First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | YL-13027 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumors | 04/21 | 06/22 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
NCT06292858: Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 93 | RoW | IMB071703 injection | Beijng Immunoah Pharma Tech Co., Ltd. | Recurrent or Metastatic, Advanced Solid Tumors | 04/25 | 08/25 | | |
NCT05552807: SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1 | 120 | RoW | SCT-I10A, SCT200, paclitaxel, docetaxel | Sinocelltech Ltd. | Head and Neck Squamous Carcinoma | 09/23 | 09/23 | | |
NCT06225856: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies |
|
|
| Recruiting | 1 | 96 | RoW | YY201 | Shanghai Yuyao Biotech Co., Ltd. | Advanced Solid Tumor, Hematological Malignancy | 12/26 | 12/26 | | |
NCT05607563: A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours |
|
|
| Recruiting | 1 | 54 | RoW | PM1009 injection, PM1009 | Biotheus Inc. | Advanced Tumor | 11/23 | 12/23 | | |
NCT04472858: A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Donafenib, CS1001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd, CStone Pharmaceuticals | Advanced Solid Tumor | 12/23 | 12/23 | | |
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Locally Advanced or Metastatic Solid Tumor | 06/25 | 12/25 | | |
NCT05429008: A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm |
|
|
| Recruiting | 1 | 99 | RoW | HMPL-A83 injection, HMPL-A83 | Hutchmed | Advanced Tumors | 06/25 | 09/25 | | |
NCT06304571: A Study of HC006 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 76 | RoW | HC006 | HC Biopharma Inc. | Advanced Solid Tumor | 03/26 | 07/26 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
NCT04659369: Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC |
|
|
| Terminated | 1 | 21 | RoW | CMAB819, Nivolumab, Opdivo | Taizhou Mabtech Pharmaceutical Co.,Ltd | Squamous Cell Carcinoma of the Head and Neck | 10/23 | 10/23 | | |
NCT06469008: A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinomas, Solid Tumor | 07/26 | 07/26 | | |
NCT05490043: A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 62 | RoW | ATG-101 | Antengene (Hangzhou) Biologics Co., Ltd. | Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma | 08/24 | 12/24 | | |
| Recruiting | 1 | 144 | US, RoW | ADRX-0706 | Adcentrx Therapeutics | Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer | 09/25 | 12/26 | | |
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 141 | Europe, Canada, Japan, US, RoW | GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227 | GlaxoSmithKline | Neoplasms | 09/28 | 09/28 | | |
